• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps

    2/11/25 9:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email

    Upstream's 2025 Automotive & Smart Mobility Cybersecurity Report reveals that 60% of cyber incidents could affect thousands to millions of connected vehicles, with massive-scale attacks more than tripling; the report emphasizes that current regulatory requirements are insufficient to address expanding cyber risks.

    ANN ARBOR, Mich., Feb. 11, 2025 /PRNewswire/ -- Upstream Security, the leading provider of cloud-based cybersecurity and data management platform purpose-built for automotive, smart mobility, and IoT ecosystem, today released the 2025 Automotive & Smart Mobility Cybersecurity Report. The annual report, returning for its seventh year, highlights that despite the increased regulatory attention, the number, scale, and severity of cyber attacks continues to grow, showing a false sense of security and resilience. Automakers and mobility stakeholders have to go beyond regulations to address the threats causing serious implications for safety, operational availability and data privacy.

    The report revealed that in 2024, 60% of cybersecurity incidents in the automotive and smart mobility sectors affected thousands to millions of mobility assets, including vehicles, EV charging stations, smart mobility apps, and connected devices. Notably, massive-scale incidents—each impacting millions of vehicles—more than tripled, rising from 5% in 2023 to 19% in 2024. This sharp increase highlights the urgent need for organizations to prioritize resilience by extending their cybersecurity efforts beyond regulatory compliance.

    The rise of software-defined and autonomous vehicles has introduced new vulnerabilities, leading to a widening cybersecurity gap. Additionally, critical infrastructure in smart mobility devices, like EV chargers and fleet management systems, has expanded the attack surface and magnified the stakes. Mobility-specific ransomware attacks surged in 2024 causing unprecedented disruptions with 108 reported ransom attacks and 214 data breaches. One of the most impactful incidents was a ransomware attack in June on a leading US-based software provider used by 15,000 automotive dealerships which resulted in halted operations for nearly three weeks, estimating losses at $1.02 billion.

    "The cybersecurity landscape across the Automotive and Smart Mobility ecosystem is poised to become more complex than ever," said Yoav Levy, CEO and co-founder of Upstream. "Cyber threats are evolving faster than the industry is prepared to handle, outpacing regulation-driven measures. Threat actors have already shifted toward large-scale, sophisticated and AI-powered attack methods, targeting not only vehicles but also interconnected systems such as EV charging infrastructure, API-driven apps, and smart mobility IoT devices. This growing attack surface demands a transformative and proactive approach to cybersecurity."

    Cyberattacks in 2024 became more sophisticated and frequent, targeting vehicles and backend systems, as well as smart mobility platforms, devices, and applications. 65% of publicly reported cyber incidents were carried out by black hat actors with malicious intent. 92% of attacks were executed remotely, supporting the surge in scale and impact, of which 85% were long-range and did not require any physical proximity to the targeted asset. The ecosystem experienced a significant surge in telematics and application server attacks in 2024— 43% of incidents in 2023 rising to 66% in 2024.

    In addition to monitoring publicly reported cyber incidents, Upstream's AutoThreat® team monitors the deep and dark web for threat actors targeting connected vehicles, mobility applications and devices. When zooming in on deep and dark web activities carried out by black hat hackers, 70% activities had the potential to impact thousands to millions of mobility assets and over 76% targeted multiple stakeholders and had a global reach.

    Additional key findings in the report include:

    • 2024 saw 409 new incidents (up from 295 in 2023), contributing to a total of 1,877 documented cases since 2010.
    • The dramatic rise in incidents is largely attributed to a sharp escalation in ransomware attacks targeting the mobility sector.
    • Data and privacy-related incidents accounted for 60% of 2024 incidents, up 20% from 2023.
    • The percentage of incidents involving car system manipulation and control of vehicle systems increased dramatically in 2024, accounting for over 35% of incidents.

    The report further delves into a range of topics including China's strategic automotive investments and impact on the cyber landscape, EV charging infrastructure risks, 2024's attack vectors and today's regulatory reality. Download the full 2025 Upstream Global Automotive & Smart Mobility Cybersecurity Report here.

    About Upstream Security

    Upstream delivers a cloud-based, AI-powered data management platform purpose-built for connected vehicles, smart mobility, and IoT ecosystem. The Upstream Platform transforms fragmented, distributed mobility data into centralized, structured, and contextualized data lakes, unlocking its full potential. By leveraging this data, Upstream empowers customers with advanced, AI-driven applications across various use cases, including proactive vehicle quality management, cybersecurity detection and response (XDR), fraud prevention, observability, usage-based insurance, and more.

    Upstream Media Contact

    Mushkie Meyer

    [email protected]

    US: +1 914 336 4035

    UK: +44 203 769 4034

     

    Cision View original content:https://www.prnewswire.com/news-releases/automotive-security-leaders-must-take-immediate-action-to-mitigate-the-surging-cyber-threatsupstream-report-reveals-critical-gaps-302373309.html

    SOURCE Upstream

    Get the next $UPB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Renaud Ronald C Jr

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:33 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ruddy Marcella K.

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chimovits Erez

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      6/12/25 4:17:31 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:19:30 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:17:52 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

      4 - Upstream Bio, Inc. (0002022626) (Issuer)

      10/17/24 4:05:04 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

      – Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first quarter of 2026 – WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an in

      7/8/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

      – Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translationa

      6/15/25 7:45:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Upstream Bio with a new price target

      Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

      11/5/24 6:29:20 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Upstream Bio with a new price target

      JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

      11/5/24 6:28:28 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Upstream Bio

      William Blair initiated coverage of Upstream Bio with a rating of Outperform

      11/5/24 6:28:02 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    SEC Filings

    See more
    • Upstream Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      6/12/25 4:18:05 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Upstream Bio Inc.

      10-Q - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:10:23 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Upstream Bio, Inc. (0002022626) (Filer)

      5/6/25 7:05:10 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    See more
    • Upstream Bio Appoints Stacy Price as Chief Technology Officer

      WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

      5/20/25 7:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Upstream Bio Appoints Allison Ambrose as General Counsel

      WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

      12/17/24 8:00:00 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      11/7/24 9:24:55 AM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Upstream Bio Inc.

      SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

      10/22/24 4:06:27 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Upstream Bio Inc.

      SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

      10/18/24 6:10:56 PM ET
      $UPB
      Biotechnology: Pharmaceutical Preparations
      Health Care